Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00538733 · OUTCOME

Median Time to Maximum Response

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma · Source last updated 2021-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
cycles
Interval / dispersion
Full Range
Time frame
from baseline to cycle with maximum response

What was measured

Median Time to maximum response, reported in cycles of treatment. One cycle = 28 days.

Analysis population: 25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.

Groups in this outcome

T-BiRD Therapy (All Patients)

25 of the 26 patients enrolled onto the were assessed for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
T-BiRD Therapy (All Patients)25

Reported measurements

Source class 1
Values in cycles · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
T-BiRD Therapy (All Patients)4Not reported17Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        7
        value
        4
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Median Time to maximum response, reported in cycles of treatment. One cycle = 28 days.
dispersion Type
Full Range
groups
  1. description
    25 of the 26 patients enrolled onto the were assessed for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.
    id
    OG000
    title
    T-BiRD Therapy (All Patients)
param Type
MEDIAN
population Description
25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.
reporting Status
POSTED
time Frame
from baseline to cycle with maximum response
title
Median Time to Maximum Response
type
SECONDARY
unit Of Measure
cycles

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice